Tanaka, T., Fujitani, M., Taoka, M., Shimomura, I., Okawa, S., Mori, S., Kuribayashi, T., Nishimura, J., Nishimura, T., Morita, A., Hara, N., Ninomiya, K., Makimoto, G., Higo, H., Rai, K., Ichihara, E., Tomida, S., Hotta, K., Togashi, Y., Maeda, Y., Kiura, K., Katayama, R. and Ohashi, K.

Afatinib overcomes osimertinib resistance via Egfr v804f mutation in a syngeneic Egfr-mutant lung cancer mouse model.
Cancer Sci., in press (2026)

Nagasaka, M., Facchinetti, F., Bigot, L., Brayé, F., Groves, M. R., Yosa, J., Wekken, A. V., Aldea, M., Besse, B., Planchard, D., Naltet, C., Katayama, R., Olaussen, K. A., Loriot, Y. and Friboulet, L.

The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib.
npj Precis. Oncol., in press (2026)

Kurosaki, T., Suzuki, S., Watanabe, Y., Kenmotsu, H., Itoh, S., Yamaguchi, M., Shiono, A., Suzuki, T., Yokoyama, T., Toi, Y., Tanaka, H., Oki, M., Tsuda, T., Ichihara, E., Azuma, K., Tanaka, H., Arai, R., Uchibori, K., Miyauchi, E., Katayama, R. and Hayashi, H.

Immune-related gene expression profiling and alectinib efficacy for patients with ALK-rearranged non-small cell lung cancer: exploratory analysis of a prospective observational study.
Lung Cancer, 216, 109416 (2026)

Suenaga, M., Mashima, T., Kawata, N., Dan, S., Seimiya, H. and Yamaguchi, K.

Preclinical identification and clinical validation of dynamic biomarkers for trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer.
ESMO Gastrointest. Oncol., 12, 100323 (2026)

Kawamoto, S., Horiguchi, H., Torigoe, D., Wakita, M., Ito, K., Sugawara, S., Zhou, X., Mikawa, T., Park, J. H., Jung, B. K., Okumura, Y., Miyagawa, H., Maruya, M., Hori, N., Uemura, K., Sugimoto, M., Matsuda, M., Mochizuki, N., Kondoh, H., Takahashi, A., Oike, Y. and Hara, E.

Reevaluating the senolytic activity of a GLS1 inhibitor and an anti-PD-1 antibody: toward greater reproducibility and methodological rigor.
EMBO Rep., in press (2026)

more